American Cancer Society gives blood tests a bigger role in colon cancer screening

The American Cancer Society has updated its colorectal cancer screening guidelines to include newer molecular tests that received FDA approval after the 2018 version of the recommendations. MedPage Today reported the update, and the practical point is not simply that another test exists. It is that blood-based screening is moving into the formal guidance physicians use when they talk with patients about realistic screening choices.

Colorectal cancer is one of the places where screening has a hard public-health logic. Early detection can change outcomes, and colonoscopy can find and remove precancerous lesions before they become cancer. That is why the ACS colorectal cancer screening recommendations are more than a specialist document. They shape primary-care conversations, gastroenterology workflows, and, often, the way health systems frame access.

The new piece is molecular screening. Instead of relying only on direct visualization of the colon or signals found in stool, blood-based tests look for cancer-associated biological markers in a blood sample. That format matters because screening programs fail when people never take the first step. Some patients avoid colonoscopy, some do not return stool tests, and some fall out of preventive care entirely. In real medicine, the most powerful screening test is often the one a patient will actually complete.

But the limitation is just as important as the expansion. A blood test for screening is not the same thing as diagnostic colonoscopy. A positive result still needs follow-up colonoscopy, because only that procedure can confirm what is happening in the colon and allow suspicious lesions to be removed. FDA approval means a test has cleared a regulatory threshold for a defined use; it does not turn that test into a complete diagnostic pathway. Broader context for medical-device clearance and approval is available through the FDA medical devices portal.

The best way to read the ACS move is as an access expansion, not as a declaration that one method has replaced all others. Colonoscopy retains a unique role because it can detect and treat in the same procedure. Stool-based tests remain important because they are noninvasive and already embedded in screening programs. Blood tests add another entry point, especially for people who otherwise would not be screened at all.

The U.S. setting matters because ACS guidance influences how clinicians, patients, and health systems discuss preventive care. Public-health material such as the CDC colorectal cancer screening overview keeps returning to the same operational problem: awareness is not enough. People need to get screened, and positive screening results need to be followed to completion.

For patients, the message should stay precise. A blood test may reduce friction, anxiety, and the logistics of starting screening. It does not remove the need for a system that can act on the result. The ACS update is not the end of the colonoscopy conversation; it is an acknowledgment that serious prevention has to meet real human behavior, not just ideal adherence.